Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
How Much Larger Is The Chronic Myeloid Leukemia (CML) Treatment Market Expected To Become By 2029 Compared With Its 2025 Level?
The chronic myeloid leukemia (cml) treatment market size has demonstrated robust growth in recent years. It is projected to increase from $8.23 billion in 2024 to $8.64 billion by 2025, reflecting a compound annual growth rate (CAGR) of 5.0%. The expansion observed in past periods can be attributed to factors such as enhanced awareness and early detection, favorable clinical trial outcomes, the progression of targeted therapies, the influence of patient advocacy and support groups, and advancements in healthcare infrastructure.
The chronic myeloid leukemia (cml) treatment market size is expected to experience significant expansion in the upcoming years. It is projected to reach $11.32 billion by 2029, growing at a compound annual growth rate (CAGR) of 7.0%. This anticipated growth during the forecast period is primarily driven by personalized medicine approaches, the application of combination therapies, increased patient access to novel treatments, government policies supporting orphan drugs, and a rise in healthcare expenditure. Key trends foreseen in this period encompass global collaboration in research, the integration of telemedicine and remote monitoring, the development of next-generation TKIs, and various treatment optimization strategies.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12084&type=smp
What Are The Top Growth Drivers Impacting The Chronic Myeloid Leukemia (CML) Treatment Market Outlook?
The increasing incidence and prevalence within the chronic myeloid leukemia (CML) population is anticipated to stimulate the expansion of the chronic myeloid leukemia (CML) treatment market moving ahead. Chronic myeloid leukemia, also known as chronic myelogenous leukemia, is a form of cancer that impacts the bone marrow and blood. This condition is distinguished by the excessive generation of immature white blood cells, specifically myeloid cells. Treatment for chronic myeloid leukemia (CML) aids in retarding the cancer’s progression and preventing its advancement to a more severe stage. For instance, in March 2023, according to the American Society of Clinical Oncology, a US-based professional organization representing physicians of all oncology sub-specialties, in the United States, approximately 35,730 persons (19,860 men and 15,870 women) are expected to receive a multiple myeloma diagnosis in 2023, and 12,590 deaths from this illness are also projected for 2023 (7,000 males and 5,590 women). Consequently, the rising incidence and prevalence of the chronic myeloid leukemia (CML) population is driving the growth of the chronic myeloid leukemia (CML) treatment market into the future.
Which Key Segments Fueling The Chronic Myeloid Leukemia (CML) Treatment Market?
The chronic myeloid leukemia (cml) treatmentmarket covered in this report is segmented –
1) By Type: Targeted Therapy; Chemotherapy; Radiation Therapy; Splenectomy; Stem Cell Transplant
2) By Drug Type: Tyrosine Kinase Inhibitors; Antimetabolites; Other Drug Types
3) By Application: Hospitals; Clinic; Other Applications
4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
Subsegments:
1) By Targeted Therapy: Tyrosine Kinase Inhibitors (TKIs); Other Targeted Agents
2) By Chemotherapy: Combination Regimens; Single-Agent Therapies
3) By Radiation Therapy: Palliative Radiation; Total Body Irradiation
4) By Splenectomy: Laparoscopic Splenectomy; Open Splenectomy
5) By Stem Cell Transplant: Allogeneic Stem Cell Transplant; Autologous Stem Cell Transplant
Which Key Trends Are Expected To Influence The Chronic Myeloid Leukemia (CML) Treatment Market In The Coming Years?
Product Innovation is a prominent trend gaining traction within the chronic myeloid leukemia (CML) treatment market. Companies involved in the chronic myeloid leukemia (CML) treatment sector are embracing advanced technologies to secure their market position. For instance, in August 2022, Novartis AG, a pharmaceutical company based in Switzerland, announced that the European Commission (EC) had approved Scemblix for the management of adult patients diagnosed with chromosome-positive chronic myeloid leukemia in the chronic phase (Ph+ CML-CP). Scemblix marks the first treatment for chronic myeloid leukemia (CML) in Europe to specifically target the ABL myristoyl pocket, a characteristic identified as a STAMP inhibitor in scientific literature. This groundbreaking mechanism provides a new therapeutic choice for patients who have developed either intolerance or resistance to existing tyrosine kinase inhibitors (TKIs). By redefining the treatment methodology, Scemblix addresses the unmet needs of those struggling with current therapies.
Who Are The Key Multinational Companies Dominating The Chronic Myeloid Leukemia (CML) Treatment Market?
Major companies operating in the chronic myeloid leukemia (CML) treatment market include Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Eisai Co. Ltd., Fresenius Kabi AG, Sun Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Incyte Corporation, Cipla Limited, Dr. Reddy’s Laboratories Ltd., Amneal Pharmaceuticals LLC, Lupin Limited, Innovent Biologics Inc., Glenmark Pharmaceuticals Limited, Il-Yang Pharmaceutical Co. Ltd., Accord Healthcare Inc., ARIAD Pharmaceuticals Inc., Orca Bio, Bio-Path Holdings Inc.
Download The Full Report For Exclusive Market Findings:
How Does The Chronic Myeloid Leukemia (CML) Treatment Market Perform Across Key Geographic Regions?
North America was the largest region in the chronic myeloid leukemia (CML) treatment market in 2024. The regions covered in the chronic myeloid leukemia (CML) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Chronic Myeloid Leukemia (CML) Treatment Market Report:
https://www.thebusinessresearchcompany.com/customise?id=12084&type=smp
Browse Through More Reports Similar to the Global Chronic Myeloid Leukemia (CML) Treatment Market 2025, By The Business Research Company
Gastrointestinal Bleeding Treatment Devices Global Market Report 2025
Gastrointestinal Devices Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/gastrointestinal-devices-global-market-report
Medical Equipment Maintenance Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/medical-equipment-maintenance-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model